Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 101–200 of 1,001
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
Xu, M., Zheng, J., Hou, T., Lin, H., Wang, T., Wang, S., Lu, J., Zhao, Z., Li, M., Xu, Y., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0323 · Cited by 108
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationDiabetic heart disease: A clinical update
Rajbhandari, J., Fernandez, C. J., Agarwal, M., Yeap, B. X. Y., & Pappachan, J. M. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.383 · Cited by 102
New strategies to improve clinical outcomes for diabetic kidney disease
Forst, T. M., Mathieu, C., Giorgino, F., Wheeler, D. C., Παπάνας, Ν., Schmieder, R. E., Halabi, A., Schnell, O., Streckbein, M., & Tuttle, K. R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02539-2 · Cited by 101
“One study, eValuation of ERTugliflozin effIcacy and safety – CardioVascular outcomes (VERTIS-CV) [48], reported no significant difference in their secondary kidney disease outcome (death due to kidney disease, kidney replacement therapy, or doubling of serum creatinine) between those randomized to ertugliflozin versus…”
BackgroundInfluentialMarin‐Neto, J. A., Rassi, A., de Oliveira, G. M. M., Correia, L. C. L., Ramos, A. N., Luquetti, A. O., Hasslocher‐Moreno, A. M., de Sousa, A. S., de Paola, Â. A. V., Sousa, A. C. S., et al. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230269 · Cited by 166
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
Seminer, A., Mulihano, A., O’Brien, C., Krewer, F., Costello, M., Judge, C., O’Donnell, M., & Reddin, C. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0360 · Cited by 91
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Kittipibul, V., Cox, Z. L., Chesdachai, S., Fiuzat, M., Lindenfeld, J. M., & Mentz, R. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.040 · Cited by 103
Management of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
BackgroundGiorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01163-9 · Cited by 95
“Renal benefits of SGLT2 inhibitors in people with T2D The renoprotective effects of SGLT2 inhibitors in people with T2D have been evaluated in five major CV outcomes trials (CVOTs): EMPA-REG OUTCOME (empagliflozin) [24], CANVAS program, which comprised two randomized, double-blind, placebo-controlled phase 3 trials: C…”
BackgroundMethodResultInfluentialNetwork Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
Zhao, M., Sun, S., Huang, Z., Wang, T., & Tang, H. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11220720 · Cited by 82
Okunrintemi, V., Mishriky, B. M., Powell, J. R., & Cummings, D. M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14211 · Cited by 86
Seferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2026 · Cited by 93
Self-citationLiu, H., Sridhar, V. S., Boulet, J., Dharia, A., Khan, A. A., Lawler, P. R., & Cherney, D. Z. I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154918 · Cited by 90
Self-citationJudge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R. J., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae263 · Cited by 91
Bhattarai, M., Salih, M., Regmi, M., Al-Akchar, M., Deshpande, R., Niaz, Z., Kulkarni, A., Siddique, M., & Hegde, S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42078 · Cited by 83
Hussain, A. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00247-3 · Cited by 97
“Once chronic hyperglycemia progresses to T2DM, a number of microvascular and macrovascular complications are concurrently established, with cardiovascular diseases (CVDs) being among the major contributors to morbidity and mortality in affected individuals [8].”
Predicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 92
Pan, H.-C., Chen, J.-Y., Chen, H.-Y., Yeh, F.-Y., Huang, T. T.-M., Sun, C.-Y., Wang, S.-I., Wei, J. C.-C., & Wu, V.-C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.50050 · Cited by 79
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Kasiakogias, A., Rosei, E. A., Camafort, M., Ehret, G., Faconti, L., Ferreira, J. P., Brguljan-Hitij, J., Januszewicz, A., Kahan, T., Manolis, A. J., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002910 · Cited by 87
Nelson, A. J., Pagidipati, N. J., Aroda, V. R., Cavender, M. A., Green, J. B., Lopes, R. D., Al-Khalidi, H., Gaynor, T., Kaltenbach, L. A., Kirk, J. K., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.053766 · Cited by 79
Self-citationA Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
Kittleson, M. M. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.03.346 · Cited by 90
Sánchez-Fructuoso, A. I., Raba, A. B., Banegas‐Deras, E. J., Vigara, L. A., Valero, R., Esteve, A. F., Vega, L. L. C., Gavela, E., González, E., Coronado, P. S., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad007 · Cited by 82
Neuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., Jun, M., Jardine, M. J., Zoungas, S., Pollock, C., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14226 · Cited by 78
Nelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78
Self-citationKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Roddick, A., Wonnacott, A., Webb, D. R., Watt, A., Watson, M. A., Staplin, N., Riding, A., Lioudaki, E., Kuverji, A., Kossi, M. E., et al. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03339-3 · Cited by 93
SGLT2-inhibitors are effective and safe in the elderly: the SOLD study
Lunati, M. E., Cimino, V., Gandolfi, A., Trevisan, M., Montefusco, L., Pastore, I., Pace, C., Betella, N., Favacchio, G., Bulgheroni, M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106396 · Cited by 77
Szarek, M. J., Bhatt, D. L., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0651 · Cited by 85
Self-citationPrattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Vedin, O., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.010 · Cited by 81
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 83
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
Santulli, G., Varzideh, F., Forzano, I., Wilson, S. M., Salemme, L., Donato, A. D., Lombardi, A., Rainone, A., Nunziata, L., Jankauskas, S. S., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20598 · Cited by 84
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Staplin, N., Roddick, A. J., Emberson, J., Reith, C., Riding, A., Wonnacott, A., Kuverji, A., Bhandari, S., Baigent, C., Haynes, R., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101163 · Cited by 74
Waijer, S. W., Vart, P., Cherney, D. Z. I., Chertow, G. M., Jongs, N., Langkilde, A. M., Mann, J. F. E., Mosenzon, O., McMurray, J. J. V., Rossing, P. R., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05694-6 · Cited by 84
Self-citationSharma, A., Ferreira, J. P., Zannad, F., Pocock, S. J., Filippatos, G., Pfarr, E., Petrini, M., Kraus, B. J., Wanner, C., Packer, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2857 · Cited by 71
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01401-8 · Cited by 72
Aimo, A., Pateras, K., Stamatelopoulos, K. S., Bayés‐Genís, A., Lombardi, C., Passino, C., Emdin, M., & Georgiopoulos, G. A. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07099-2 · Cited by 74
“The eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTISCV) was not included because of the lack of a clearly defined HFrEF subgroup [26].”
MethodCroteau, D., Luptak, I., Chambers, J. M., Hobai, I., Panagia, M., Pimentel, D. R., Siwik, D. A., Qin, F., & Colucci, W. S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019995 · Cited by 73
Oyama, K., Raz, I., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Park, K. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab530 · Cited by 80
“Latin America 198 (13) 725 (13) 571 (10) 263 (9) 118 (7)”
InfluentialSelf-citationMark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 87
Seidu, S., Alabraba, V., Davies, S., Newland‐Jones, P., Fernando, K., Bain, S. C., Diggle, J., Evans, M., James, J., Kanumilli, N., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01550-5 · Cited by 97
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 76
“Lower rate of hHF, and a trend towards improved renal outcome VERTIS-CV [48]”
BackgroundResultInfluentialEmpagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
Hu, Z., Ju, F., Du, L., & Abbott, G. W. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01392-6 · Cited by 73
“Several major clinical cardiovascular outcome trials, such as the EMPAREG outcome trial [2], CANVAS trial [20], DECLARETIMI 58 trial [21], and VERTIS-CV trial [22] have all shown that SGLT2 inhibitors can significantly reduce the risk of cardiovascular complications, cardiovascular mortality and heart failure hospital…”
BackgroundLi, N., Lv, D., Zhu, X., Wei, P., Gui, Y., Liu, S., Zhou, E., Zheng, M., Zhou, D. F., & Zhang, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.728089 · Cited by 75
“Among them, four (8, 9, 17, 18) included patients with type 2 diabetes, two (11, 19) included patients with diabetic kidney disease, two (7, 20) included patients with heart failure, and three (10, 11, 19) included patients with CKD.”
BackgroundLee, M. M. Y., Ghouri, N., McGuire, D. K., Rutter, M. K., & Sattar, N. A. (2021) · Diabetes Care · doi:10.2337/dc20-3007 · Cited by 73
Self-citationChronic kidney disease in patients with diabetes mellitus
Nordheim, E., & Jenssen, T. G. (2021) · Endocrine Connections · doi:10.1530/ec-21-0097 · Cited by 89
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2351 · Cited by 80
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
Rau, M., Thiele, K., Hartmann, N. K., Schuh, A., Altiok, E., Möllmann, J., Keszei, A. P., Böhm, M., Marx, N., & Lehrke, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01175-5 · Cited by 76
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 67
SGLT2 inhibitors: Beyond glycemic control
Hasan, I., Rashid, T., Jaikaransingh, V., Heilig, C., Abdel‐Rahman, E. M., & Awad, A. S. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100335 · Cited by 89
Ketoacidosis and SGLT2 Inhibitors: A Narrative Review
Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., Russo, G. T., et al. (2024) · Metabolites · doi:10.3390/metabo14050264 · Cited by 75
“Finally, a similar frequency of diabetic ketoacidosis was reported for ertugliflozin in the VERTIS-CV trial (the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial): 0.3% in the 5 mg ertugliflozin group, 0.4% in 15 mg group and 0.1% in the placebo group [45].”
BackgroundInfluentialHerrington, W. G., Savarese, G., Haynes, R., Marx, N., Mellbin, L., Lund, L. H., Dendale, P., Seferovic, P., Rosano, G., Staplin, N., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2286 · Cited by 63
Self-citationKetones: the double-edged sword of SGLT2 inhibitors?
Lupsa, B. C., Kibbey, R. G., & Inzucchi, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05815-1 · Cited by 76
“In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 DiabetesMellitus Patients (EMPA-REGOUTCOME), participants with type 2 diabetes and underlying CVD randomised to empagliflozin had a lower rate of the primary MACE outcome (composite of death from CV causes, nonfatal myocardial infarction [MI] or nonfata…”
BackgroundInfluentialGuideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 78
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Self-citationNikolaou, P., Mylonas, N., Makridakis, M., Makrecka‐Kuka, M., Iliou, A., Zerikiotis, S., Efentakis, P., Kampoukos, S., Kostomitsopoulos, N. G., Vilšķe̅rsts, R., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00934-7 · Cited by 71
“EMPA (in EMPA-REG OUTCOME trial) [102], DAPA (in DAPA-HF) [57, 91] and CANA (in CANVAS and CREDENCE trials) [63, 69] demonstrated superiority regarding cardiovascular death in comparison to placebo; ERTU in VERTIS-CV trial met the pre-specified criterion for noninferiority with respect to MACE, though it was not super…”
ResultSGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Rolek, B., Haber, M., Gajewska, M., Rogula, S., Pietrasik, A., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080322 · Cited by 77
“In the VERTIS trial [24], 8246 patients were enrolled and randomly assigned to ertugliflozin 5 mg, 15 mg, or a placebo once daily.”
MethodDrake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 74
Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 70
“The weight change observed with ertugliflozin 5 mg or 15 mg in the VERTIS CV trial [28] was”
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Li, J., Yu, Y., Sun, Y., Yu, B., Tan, X. W., Wang, B., Lu, Y., & Wang, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02019-8 · Cited by 74
SGLT2 Inhibitors: The Sweet Success for Kidneys
Dharia, A., Khan, A. A., Sridhar, V. S., & Cherney, D. Z. I. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102135 · Cited by 69
Self-citationKDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 62
Riley, D. R., Essa, H., Austin, P., Preston, F., Kargbo, I., Ibarburu, G. H., Ghuman, R., Cuthbertson, D. J., Lip, G. Y. H., & Alam, U. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15185 · Cited by 59
SGLT-2 inhibitors as cardio-renal protective agents
Caruso, I., & Giorgino, F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154937 · Cited by 63
Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial
Kang, D., Park, S., Shin, S., Hwang, I., Yoon, Y. E., Kim, H., Kim, M., Kim, M., Yun, S., Song, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069144 · Cited by 64
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 67
Kwon, O., Myong, J., Lee, Y., Choi, Y.-J., Yi, J. E., Seo, S. M., Jang, S.-W., Kim, P. J., & Lee, J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027824 · Cited by 60
Mancini, G. B. J., O’Meara, E., Zieroth, S., Bernier, M., Cheng, A. Y. Y., Cherney, D. Z. I., Connelly, K. A., Ezekowitz, J., Goldenberg, R. M., Leiter, L. A., et al. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.04.029 · Cited by 56
Self-citationLi, D., Liu, Y., Hidru, T. H., Yang, X., Wang, Y., Chen, C., Li, K. H. C., Tang, Y., Wei, Y., Tse, G., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.619586 · Cited by 63
“Ertugliflozin: NCT01986881 (56) 2020 64.”
Mascolo, A., Scavone, C., Scisciola, L., Chiodini, P., Capuano, A., & Paolisso, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105836 · Cited by 60
Wang, H., Li, T., Sun, F., Liu, Z., Zhang, D., Teng, X., Morel, L. M., Wang, X., & Ye, S. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002686 · Cited by 60
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Lee, Y., Lim, S. K., & Davies, M. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01170-4 · Cited by 76
“By contrast, in the VERTIS CV trial 15 , ertugliflozin was non-inferior to placebo for MACE without superiority.”
Farmer, R. E., Beard, I., Raza, S. I., Gollop, N. D., Patel, N., Tebboth, A., McGovern, A. P., Kanumilli, N., & Ternouth, A. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.12.015 · Cited by 56
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Abdeldayem, T. K., Younis, O., Zarif, B., Attia, S., & AbdelSalam, A. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.03.002 · Cited by 62
SGLT1: A Potential Drug Target for Cardiovascular Disease
Zhao, M., Li, N., & Zhou, H. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s418321 · Cited by 62
“According to VERTIS CV clinical trial, ertugliflozin was non-inferior to placebo in terms of major cardiovascular adverse events in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD).(21) A recent meta-analysis included 13 randomized clinical trials showed that SGLT2 inhibitors significantly reduced…”
MethodZhang, H., Ding, L., Mi, L., Zhang, A.-K., Zhang, K., Jiang, Z., Yu, F., Yan, X.-X., Shen, Y.-J., & Tang, M. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad356 · Cited by 58
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin, J., Xu, Y., Chang, A. R., Carrero, J. J., Flaherty, C. M., Mukhopadhyay, A., Inker, L. A., Blecker, S., Horwitz, L. I., & Grams, M. E. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.057 · Cited by 67
Martínez, J. J. G., Górriz, J. L., Cuenca, A. M. C., Conde, A. C., & Velasco, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216509 · Cited by 62
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Kolesnik, E., Scherr, D., Rohrer, U., Benedikt, M., Manninger, M., Sourij, H., & von Lewinski, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031678 · Cited by 60
“This paradigm shift is due to the impressive reduction of reported events of hospitalization for heart failure in the respective outcome trials of empagliflozin [4], dapagliflozin [5], canagliflozin [6], sotagliflozin [7], and ertugliflozin [8] in patients with diabetes.”
BackgroundXu, J., Hirai, T., Koya, D., & Kitada, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010137 · Cited by 57
Ujjawal, A., Schreiber, B., & Verma, A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221090001 · Cited by 57
Salah, H. M., Al'Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., Mounsey, J. P., Greene, S. J., McGuire, D. K., Lopes, R. D., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.12.007 · Cited by 52
Self-citationBidulka, P., Lugo-Palacios, D. G., Carroll, O., O’Neill, S., Adler, A., Basu, A., Silverwood, R. J., Bartlett, J. W., Nitsch, D., Charlton, P., et al. (2024) · BMJ · doi:10.1136/bmj-2023-077097 · Cited by 63
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Self-citationEfficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
Scheen, A. J., & Bonnet, F. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101419 · Cited by 51
Silverii, G. A., Monami, M., & Mannucci, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14286 · Cited by 51
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Salah, H. M., Verma, S., Santos‐Gallego, C. G., Bhatt, A. S., Vaduganathan, M., Khan, M. S., Lópes, R. D., Alaref, S. J., McGuire, D. K., & Fudim, M. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10220-5 · Cited by 54
Self-citationEvans, M., Morgan, A. R., Davies, S., Beba, H., & Strain, W. D. (2022) · Age and Ageing · doi:10.1093/ageing/afac201 · Cited by 54
“Ertugliflozin VERTIS-CV [51] T2DM ≥65 years”
Scheen, A. J. (2024) · Drugs · doi:10.1007/s40265-024-02090-9 · Cited by 59
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
de Mortanges, A. P., Salvador, D., Laimer, M. W., Muka, T., Wilhelm, M., & Bano, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751214 · Cited by 55
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis
Hanlon, P., Butterly, E. W., Wei, L. S., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2025) · JAMA · doi:10.1001/jama.2024.27402 · Cited by 61
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.